Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

Both Ozempic and Wegovy are forms of semaglutide ... This news comes less than a month after Mounjaro and Zepbound, also ...

Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...

RBC Capital Markets analyst Brian Abrahams notes weight-loss drugs like Novo's Wegovy and Eli Lilly's Zepbound "have been an ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...

The demand for bariatric operations dropped sharply last year as use of anti-obesity drugs such as Wegovy surged, study finds ...

Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up ...

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...

Wegovy is a Food and Drug Administration (FDA)-approved weight loss injection that you can only get with a prescription from a licensed healthcare professional. Experts share what to keep in mind ...

Eli Lilly ( LLY) is planning to advertise its blockbuster weight-loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided ...

Sales of Eli Lilly’s (LLY) blockbuster weight loss drug Zepbound are still booming, but just not at the level Wall Street was ...